Please assess the completion status of the following clinical trial:

Trial Title: Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have had histologic verification of AML at original diagnosis~* Patient must have one of the following:~  * Recurrent disease with \>= 5% blasts in the bone marrow (M2/M3 bone marrow), with or without extramedullary disease.~ * Recurrent disease with an absolute blast count greater than 1,000 per microliter in the peripheral blood with or without extramedullary disease~* To be eligible for the dose-finding phase: (the dose-finding phase completed in 12/2016)~  * Relapsed patients~    * Patients must be in first relapse, and~   * Patients must not have received prior re-induction therapy~ * Refractory patients~    * Patients must not have received more than one attempt at remission induction, which may consist of up to two different therapy courses; Children Oncology Group (COG) AAML1031 de novo therapy including induction I and induction II is an example~ * Treatment-related AML (t-AML)~    * Patients must be previously untreated for secondary AML~* To be eligible for the phase 2 efficacy phase:~  * Relapse patients:~    * Patients must be in first marrow relapse, and~   * Patients must not have received prior re-induction therapy; donor lymphocyte infusion (DLI) is considered a re-induction attempt~* Patients must have the status of CNS1 or CNS2 only, and no clinical signs or neurologic symptoms suggestive of CNS leukemia, such as cranial palsy~* Patients must have a performance status corresponding to an Eastern Cooperative Oncology Group (ECOG) scores of 0, 1 or 2; use Karnofsky for patients \> 16 years of age and Lansky for patients =\< 16 years of age; Note: patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score~* Patients must have recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, stem cell transplant or radiotherapy prior to entering this study; all prior treatment-related toxicities must have resolved to =\< grade 2 prior to enrollment~* Myelosuppressive chemotherapy: must not have received myelosuppressive chemotherapy within 3 weeks of entry onto this study (excluding hydroxyurea)~  * Cytoreduction with hydroxyurea can be initiated and continued for up to 24 hours prior to the start of CPX-351~* Biologic (anti-neoplastic agent): at least 7 days since the completion of therapy with a biologic agent such as steroids, retinoids; Note: for agents that have known adverse events occurring beyond 7 days after administration (i.e. monoclonal antibodies), this period must be extended beyond the time during which acute adverse events are known to occur~* Radiation therapy (RT): \>= 2 weeks for local palliative RT (small port); \>= 6 months must have elapsed if prior craniospinal RT or if \>= 50% radiation of pelvis; \>= 6 weeks must have elapsed if other substantial bone marrow (BM) radiation; Note: patients must have received =\< than 13.6 Gray (Gy) prior radiation to the mediastinum~* Stem cell transplant (SCT): no evidence of active graft vs. host disease for at least 4 weeks; for allogeneic SCT patients, \>= 3 months must have elapsed since transplant~  * Must have received no more than 1 prior autologous or allogeneic stem cell transplant.~ * Patients must be off all systemic immunosuppressive therapy for at least 2 weeks, excluding hydrocortisone for physiologic cortisol replacement~* Intrathecal cytotoxic therapy:~  * No waiting period is required for patients having received intrathecal cytarabine, methotrexate, and/or hydrocortisone~ * At least 14 days must have elapsed since receiving liposomal cytarabine (DepoCyte) by intrathecal injection~* Growth factors:~  * Patients must not have received growth factors for 7 days prior to CPX-351~ * Patients must not have received pegfilgrastim for 14 days prior to CPX-351~* Creatinine clearance or radioisotope glomerular filtration rate (GFR) \>= 70 mL/min/1.73 m\^2 or a serum creatinine based on age/gender as follows:~  * Age 1 to \< 2 years: maximum serum creatinine 0.6 mg/dL (males and females)~ * Age 2 to \< 6 years: maximum serum creatinine 0.8 mg/dL (males and females)~ * Age 6 to \< 10 years: maximum serum creatinine 1.0 mg/dL (males and females)~ * Age 10 to \< 13 years: maximum serum creatinine 1.2 mg/dL (males and females)~ * Age 13 to \< 16 years: maximum serum creatinine 1.5 mg/dL (males) and 1.4 mg/dL (females)~ * Age \>= 16 years: maximum serum creatinine 1.7 mg/dL (males) and 1.4 mg/dL (females)~* Direct bilirubin \< 1.5 x upper limit of normal (ULN) for age and institution~* Serum glutamate pyruvate (SGPT) (alanine aminotransferase \[ALT\]) =\< 3.0 x upper limit of normal (ULN) for age and institution (unless it is related to leukemic involvement)~* Shortening fraction of \>= 27% by echocardiogram, or~* Ejection fraction of \>= 50% by radionuclide angiogram or echocardiogram~* Corrected QT (using Bazett's formula \[QTcB\]) interval \< 500 msecs~* Patients with seizure disorder may be enrolled if on anticonvulsants and if seizures are well controlled~* Central nervous system (CNS) toxicity =\< grade 2~* Patients with a known history of human immunodeficiency virus (HIV) are eligible, if they meet all of the following conditions:~  * No history of HIV complications with the exception of cluster of differentiation (CD)4 count \< 200 cells/mm\^3~ * No antiretroviral therapy with overlapping toxicity such as myelosuppression~ * HIV viral loads below the limit of detection~ * No history of highly active antiretroviral therapy (HAART)-resistant HIV~* All patients and/or their parents or legal guardians must sign a written informed consent~* All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met~Exclusion Criteria:~* Patients who have received \> 450 mg/m\^2 daunorubicin equivalents; patients who relapse after receiving AAML0531/AAML1031 therapy will be eligible for this study, provided they have not received any additional anthracyclines; NOTE: for the purposes of determining eligibility for this protocol, the following cardiotoxicity multipliers will be used to determine daunorubicin equivalents:~  * Doxorubicin (doxorubicin hydrochloride): 1~ * Mitoxantrone: 3~ * Idarubicin: 3~ * Epirubicin: 0.5~* Patients who are currently receiving another investigational drug~* Patients receiving medications for treatment of left ventricular systolic dysfunction~* Patients with any of the following diagnoses:~  * Acute promyelocytic leukemia (APL)~ * Down syndrome~ * Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known bone marrow failure syndrome~ * Wilson's disease and any other disorder of copper metabolism~ * Juvenile myelomonocytic leukemia (JMML)~* Patients with documented active, uncontrolled infection at the time of study entry~* Patients with known active hepatitis B virus (HBV) and hepatitis C virus (HCV) infections~* Patients with prior allergy to daunorubicin and/or cytarabine~* Female patients who are pregnant are ineligible~* Lactating females are not eligible~* Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained~* Sexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of their study participation and for 6 months after the last dose of chemotherapy

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (CPX-351 and FLAG) (Type: EXPERIMENTAL): COURSE 1: Patients receive cytarabine IT on day 0 and at day 28-30 or up to 7 days prior to day 1 of course 2, and liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1, 3, and 5. Patients with CNS1 receive no further CNS-directed therapy in course 1. Patients with CNS2 disease may receive additional 4-6 doses of cytarabine IT twice weekly starting 48 hours after the third dose of liposome-encapsulated daunorubicin-cytarabine until CNS is clear at the discretion of the investigator. Patients meeting criteria for CR, CRp, and CRi may proceed to course 2.~COURSE 2: Patients receive filgrastim on days 1-5 and then on day 15 until blood count recovery, and fludarabine phosphate IV over 30 minutes and high-dose cytarabine IV over 1-3 hours QD on days 1-5.

Based on this trial design, predict the completion outcome and termination type (if applicable).